Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
These questions and answers are intended to provide additional helpful advice to applicants for marketing authorisations in relation to the new requirements for Braille under article 56(a) of Council Directive 2001/83/EC (as amended). This document is complementary to the following guidance already issued by the European Commission and should be read in conjunction with it:
› Guidance concerning the Braille requirements for labelling and the package leaflet
Questions and answers to address issues of national application of the new provisions concerning Braille on labelling and in the patient information leaflet of all medicines 
